Budget Amount *help |
¥23,140,000 (Direct Cost: ¥17,800,000、Indirect Cost: ¥5,340,000)
Fiscal Year 2018: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
Fiscal Year 2017: ¥7,670,000 (Direct Cost: ¥5,900,000、Indirect Cost: ¥1,770,000)
Fiscal Year 2016: ¥8,580,000 (Direct Cost: ¥6,600,000、Indirect Cost: ¥1,980,000)
|
Outline of Final Research Achievements |
The frequency and function of fusion genes in ovarian cancer remained unclear. Our aim of this study was to identify fusion genes in ovarian cancer through RNA sequencing data analysis and to clarify clinical significance of fusion genes in ovarian cancer. We performed RNA sequencing for 57 ovarian clear cell carcinoma samples and detected fusion genes based on our PRADA algorithm. Of 57 samples, ten harbored at least one therapeutically targetable fusion gene such as kinase fusion genes. In addition, 18 samples had at least one fusion gene which might be recognized as a neoantigen by host. In conclusion, gene fusion was one of important genomic alterations in clinical field as well as tumorigenesis.
|